Advances in Pharma Business Management and Research: Volume 1
Editat de Lars Schweizer, Theodor Dingermann, Otto Quintus Russe, Christian Jansenen Limba Engleză Hardback – 20 feb 2020
The chapters are summaries of master’s theses by "high potential" Pharma MBA students from the Goethe Business School, Frankfurt/Main, Germany, with 8-10 years of work experience and are based on scientific know-how and real-world experience. The authors applied their interdisciplinary knowledge gained in 22 months of studies in the MBA program to selected practical themes drawn from their daily business.
| Toate formatele și edițiile | Preț | Express |
|---|---|---|
| Paperback (1) | 401.77 lei 6-8 săpt. | |
| Springer International Publishing – 18 sep 2020 | 401.77 lei 6-8 săpt. | |
| Hardback (1) | 408.91 lei 6-8 săpt. | |
| Springer International Publishing – 20 feb 2020 | 408.91 lei 6-8 săpt. |
Preț: 408.91 lei
Nou
Puncte Express: 613
Preț estimativ în valută:
78.27€ • 82.07$ • 64.67£
78.27€ • 82.07$ • 64.67£
Carte tipărită la comandă
Livrare economică 29 ianuarie-12 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783030359171
ISBN-10: 3030359174
Pagini: 85
Ilustrații: X, 85 p. 11 illus.
Dimensiuni: 155 x 235 mm
Greutate: 0.32 kg
Ediția:1st ed. 2020
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
ISBN-10: 3030359174
Pagini: 85
Ilustrații: X, 85 p. 11 illus.
Dimensiuni: 155 x 235 mm
Greutate: 0.32 kg
Ediția:1st ed. 2020
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
Cuprins
Chapter 1. Introduction: Trends and developments in the pharmaceutical and life sciences industry.- Chapter 2. Relevance of instruments for measurements of Quality of Life in the AMNOG Context.- Chapter 3. The quality management system for R&D project and portfolio management in a pharmaceutical company.- Chapter 4. Brexit and Its Impact on Pharmaceutical Law - Implications for global pharma companies.- Chapter 5. Implementation of Measurable and Sustainable Actions to Improve Employee’s Engagement and Business Performance - Global Medical Clinical & Regulatory Affairs (GMCRA) – A Role Model at Fresenius Kabi.- Chapter 6. Leadership Models and Work Behavior: An Empirical Analysis of Consequences of Authentic and Transformational Leadership.- Chapter 7. Alliance Management at Merck - Establishing an operational 100-day plan for alliance launches and management.
Notă biografică
Dr. Lars Schweizer
Prof. Dr. Lars Schweizer has been a Professor of Strategic Management at Goethe University Frankfurt since December 2007. Currently, he is the Academic Director of the Master of Pharma Business Administration as well as the Master of Digital Transformation at Goethe Business School. He holds a doctoral degree and postdoctoral degree (habilitation) from the University of Bamberg. He has published papers in journals such as the Academy of Management Journal, the Strategic Management Journal, the Journal of Management, Industrial and Corporate Change, the Journal of General Management, Scandinavian Journal of Management, the Journal of Engineering and Technology Management, the International Journal of Biotechnology, Pharmaceutical Policy and Law, and the Journal of Business Research. His main research focuses are mergers & acquisitions, strategic management, leadership, and organizational behavior as well as the pharmaceutical and biotechnology industries.
Dr. Theodor Dingermann
Prof. Dr. rer. nat. Theodor Dingermann (1948) studied Pharmacy at the University of Erlangen-Nurnberg between 1973 and 1976. In 1980 he received his Ph.D. in Biochemistry. From 1980 to 1982 he worked as a postdoctoral fellow at Yale University, New Haven, USA with Prof. Dr. Dieter Söll. From 1990 to 2013 he was a Professor and Director of the Department of Pharmaceutical Biology at Goethe University Frankfurt/Main. Since 2013 he has been affiliated with the Goethe University as a Senior Professor. Prof. Dingermann received the Carl-Mannich-Medal Award from the German Pharmaceutical Society in 2010, and he was elected “Professor of the Year 2009” in Germany. He is editor-in-chief of the international scientific journal DIE PHARMAZIE, editor-in-chief of “Pharmakon”, the official journal of the German Pharmaceutical Society, and a member of the group of chiefeditors of the “Pharmazeutische Zeitung”. Between 2005 and 2014, Prof. Dingermann was the Representative for Biotechnology for the State of Hessen. He is an elected member of the German Pharmaceutical Association’s Drug Commission (Arzneimittelkommission der Deutschen Apothekerschaft) and since 1992 has been Chairman of the working group "recombinant DNA products" of the German Pharmacopoeia committee at the BfArM. From 1996 to 2000 he was Vice President and from 2000 to 2004 President of the German Pharmaceutical Society (DPhG). From 1998 to 2000 he served as Vice President of Goethe University Frankfurt/Main.
At GBS, Prof. Dr. Dingermann is the Academic Director of the Master of Pharma Business Administration.
He is in great demand as a speaker at international events and author of numerous publications.
Dr. Otto Quintus Russe
Dr. Otto Quintus Russe has been the Managing Director of the House of Pharma & Healthcare at Goethe University Frankfurt since 2014. He studied Pharmacy at Goethe University Frankfurt from 2004 to 2008. After working in the pharmaceutical industry and public pharmacy, he completed his doctorate (2010-2014) on AMP-activated protein kinase as a target for the treatment of inflammatory nociception at the University Hospital Frankfurt.
Dr. Christian Jansen
Christian Jansen has been the Managing Director of Goethe Business School since 2013. Prior to joining GBS, Dr. Jansen worked as a consultant with McKinsey & Company for three years. He holds a diploma in Business Administration from Goethe University Frankfurt and a Master of Business Administration (MBA) degree from the University of Iowa, USA. In 2008, he completed his doctorate at the European Business School.
Prof. Dr. Lars Schweizer has been a Professor of Strategic Management at Goethe University Frankfurt since December 2007. Currently, he is the Academic Director of the Master of Pharma Business Administration as well as the Master of Digital Transformation at Goethe Business School. He holds a doctoral degree and postdoctoral degree (habilitation) from the University of Bamberg. He has published papers in journals such as the Academy of Management Journal, the Strategic Management Journal, the Journal of Management, Industrial and Corporate Change, the Journal of General Management, Scandinavian Journal of Management, the Journal of Engineering and Technology Management, the International Journal of Biotechnology, Pharmaceutical Policy and Law, and the Journal of Business Research. His main research focuses are mergers & acquisitions, strategic management, leadership, and organizational behavior as well as the pharmaceutical and biotechnology industries.
Dr. Theodor Dingermann
Prof. Dr. rer. nat. Theodor Dingermann (1948) studied Pharmacy at the University of Erlangen-Nurnberg between 1973 and 1976. In 1980 he received his Ph.D. in Biochemistry. From 1980 to 1982 he worked as a postdoctoral fellow at Yale University, New Haven, USA with Prof. Dr. Dieter Söll. From 1990 to 2013 he was a Professor and Director of the Department of Pharmaceutical Biology at Goethe University Frankfurt/Main. Since 2013 he has been affiliated with the Goethe University as a Senior Professor. Prof. Dingermann received the Carl-Mannich-Medal Award from the German Pharmaceutical Society in 2010, and he was elected “Professor of the Year 2009” in Germany. He is editor-in-chief of the international scientific journal DIE PHARMAZIE, editor-in-chief of “Pharmakon”, the official journal of the German Pharmaceutical Society, and a member of the group of chiefeditors of the “Pharmazeutische Zeitung”. Between 2005 and 2014, Prof. Dingermann was the Representative for Biotechnology for the State of Hessen. He is an elected member of the German Pharmaceutical Association’s Drug Commission (Arzneimittelkommission der Deutschen Apothekerschaft) and since 1992 has been Chairman of the working group "recombinant DNA products" of the German Pharmacopoeia committee at the BfArM. From 1996 to 2000 he was Vice President and from 2000 to 2004 President of the German Pharmaceutical Society (DPhG). From 1998 to 2000 he served as Vice President of Goethe University Frankfurt/Main.
At GBS, Prof. Dr. Dingermann is the Academic Director of the Master of Pharma Business Administration.
He is in great demand as a speaker at international events and author of numerous publications.
Dr. Otto Quintus Russe
Dr. Otto Quintus Russe has been the Managing Director of the House of Pharma & Healthcare at Goethe University Frankfurt since 2014. He studied Pharmacy at Goethe University Frankfurt from 2004 to 2008. After working in the pharmaceutical industry and public pharmacy, he completed his doctorate (2010-2014) on AMP-activated protein kinase as a target for the treatment of inflammatory nociception at the University Hospital Frankfurt.
Dr. Christian Jansen
Christian Jansen has been the Managing Director of Goethe Business School since 2013. Prior to joining GBS, Dr. Jansen worked as a consultant with McKinsey & Company for three years. He holds a diploma in Business Administration from Goethe University Frankfurt and a Master of Business Administration (MBA) degree from the University of Iowa, USA. In 2008, he completed his doctorate at the European Business School.
Textul de pe ultima copertă
This open access book presents a unique collection of practical examples from the field of pharma business management and research. It covers a wide range of topics such as: 'Brexit and its Impact on pharmaceutical Law - Implications for Global Pharma Companies', 'Implementation of Measures and Sustainable Actions to Improve Employee's Engagement', 'Global Medical Clinical and Regulatory Affairs (GMCRA)', and 'A Quality Management System for R&D Project and Portfolio Management in a Pharmaceutical Company'.
The chapters are summaries of master’s theses by "high potential" Pharma MBA students from the Goethe Business School, Frankfurt/Main, Germany, with 8-10 years of work experience and are based on scientific know-how and real-world experience. The authors applied their interdisciplinary knowledge gained in 22 months of studies in the MBA program to selected practical themes drawn from their daily business.
The chapters are summaries of master’s theses by "high potential" Pharma MBA students from the Goethe Business School, Frankfurt/Main, Germany, with 8-10 years of work experience and are based on scientific know-how and real-world experience. The authors applied their interdisciplinary knowledge gained in 22 months of studies in the MBA program to selected practical themes drawn from their daily business.
Caracteristici
Unique combination of management and pharmaceutical content Cutting edge information of scientific and practical issues in the pharmaceutical industry Explorations of pharmaceutical late-breaking topics where science meets business